Summary Folinic acid (FA) and cisplatin (CIDDP) both potentiate the cytotoxicity of 5-fluorouracil (5-FU). The activity of various drug combinations including 5-FU, CDDP and FA was tested on two human cell lines derived from squamous cell carcinomas of the head and neck. Cytotoxicity was assessed by the semiautomated colorimetric MTT test. The drugs were tested in clinically achievable conditions (concentrations and duration of exposure). The dose response curves for 5-FU (0-100 ng ml-') associated with FA (I-7-10' M) reflected a progressive increase in 5-FU cytotoxicity with increasing FA concentrations. When CDDP (0-5 lgml ') was associated with 5-FU, CDDP-mediated enhancement of 5-FU cytotoxicity was apparent only when CDDP was given before 5-FU. The triple association CDDP, 5-FU and FA was also tested. In this case, for an identical final cytotoxicity, the presence of FA (10-6 M) permitted reduction of the 5-FU concentration between 24.2 and 42% and reduction of the CDDP concentration between 13.8 and 72.7%. These observations may be beneficial for the design of more rational therapeutic trials associating CDDP, 5-FU and FA.
5-fluorouracil (5-FU) is increasingly used in the treatment of several types of malignancies, although not because of the efficacy of the drug itself. For example, even though 5-FU is widely used for the management of colorectal adenocarcinoma, it still has a disappointingly low efficacy when administered alone in this pathology (Moertel, 1978; Cohen et al., 1989) . The renewed interest is linked to the results obtained with various drug combinations, and in particular 5-FU plus cisplatin (CDDP) for treatment of head and neck cancer (Kish et al., 1982; Amrein & Weitzman, 1985; Thyss et al., 1986) , and 5-FU plus folinic acid (FA), which significantly improves the response rate in colorectal carcinoma (Machover et al., 1986; Rustum, 1989; O'Connell, 1989; Arbuck, 1989) . The improved results obtained when 5-FU is administered in combination can be explained biochemically: reduced folates enhance the inhibition of thimidilate synthetase (TS) by 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), an active form of 5-FU (Houghton et al., 1982; Kerr, 1989) . Although less work has been conducted on 5-FU potentiation by CDDP, a cisplatininduced increase in intracellular levels of reduced folates may also be the central mechanism in CDDP-5-FU synergism (Scanlon et al., 1986) . Tests of the triple association 5-FU-CDDP-FA were a logical consequence; not surprisingly, the first noncontrolled clinical trials have been reported recently. Objective responses have been observed for heavily pretreated patients with breast (Hart et al., 1989; Allegra et al., 1989) , gastrointestinal (Leong et al., 1989; Fernandes et al., 1989) , and head and neck carcinomas . However, severe toxicity has also occurred, and has reportedly caused a number of deaths (Leong et al., 1989) . These clinical trials differed considerably as concerns the drug sequences and dosages of 5-FU, CDDP and FA. Experimental data are required to develop rational guidelines for optimizing synchronisation of these three products and for analysis of the relative roles of CDDP and FA when combined with 5-FU. In an attempt to obtain such information, the present experimental study was developed using human cell cultures from head and neck carcinoma.
Material and method
Chemicals 5-FU was obtained from ROCHE Laboratories (Neuilly, France), in an injectable form dissolved in H20 (final concentration 0.385 M). CDDP was obtained from R. Bellon Laboratories (Paris, France), in an injectable form dissolved in 0.9% NaCl (final concentration 1.66 10-3 M). FA (d,l) was obtained from Sigma (La Verpilliere, France), as a powder that was dissolved just before use in H20 at a final concentration of 10-2 M. These stock solutions were stored at -200C.
The MTT test (Carmichael et al., 1987) was performed with 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) and DMSO, both from SIGMA. DMEM medium, glutamine and foetal bovine serum (FBS) were purchased from GIBCO (Paisley, GB). Penicillin and streptomycin were from MERIEUX (Lyons, France).
Cell lines CAL 27 and CAL 33 were established in our institute (Gioanni et al., 1988) The dose response curves for 5-FU combined with FA are shown on Figure 2 for various FA concentrations (10-7 to 10-5 M). 5-FU activity increased progressively for both cell lines as the FA concentration rose. When the FA concentration changed from 0 to 10-5 M, the ICm (ng ml-') for CAL 27 and CAL 33 changed from 27.1 to 9.7 and from 44.4 to 27.1 respectively (Table II) . Figure 3 shows the dose response curves for cell line CAL 27 when 5-FU was combined with CDDP before, during and after exposure to 5-FU. CDDP-mediated enhancement of 5-FU cytotoxicity was apparent only when CDDP was given before or at the same time as 5-FU. It can be seen that the data compare well from the two separate experiments ( Figure 3a Predicted effect: product of the specific effect of 5-FU multiplied by the specific effect of CDDP for a given combination. a, CDDP 6 h before 5-FU; b, CDDP and 5-FU together; c, CDDP 6 h after 5-FU. For details see Table I ; dotted lines = regression lines for the data shown; solid lines = 95% confidence interval; dashed lines = theoretical line for equivalence between observed and theoretical effects. Statistics: for a, the Wilcoxon rank test gave a two-tailed probability P = 0.0284; Spearman rank-correlation r = 0.959, P = 0.0024. For b, the Wilcoxon rank test gave a two-tailed probability P = 0.1973; Spearman rank-correlation r = 0.964, P = 0.0023. For c, the Wilcoxon rank test gave a two-tailed probability P = 0.0684; Spearman rank-correlation r = 0.950, P = 0.0027. = 1 fig ml1' ) to 24.2% (CDDP concentration = 2.5 yg ml1 ); inversely, the CDDP concentration could be reduced from 13.8% (5-FU concentration = 10 ng ml') to 72.7% (5-FU concentration = 17.5 ng mlh') (Table III) . tion, Figure 4 compares the cytotoxic effects actually produced by the drug combination with the effects predicted from results obtained with each drug used alone. These graphs and statistical analysis reveal that administration of CDDP before 5-FU leads to more than additive effects; by contrast, when CDDP was administered at the same time as 5-FU, mere additivity of the effects was noted; finally, when CDDP was used after 5-FU, less than addivity of effects occurred (observed effects lower than predicted effects, with a trend towards statistical significance). The data shown for the sequence CDDP followed by 5-FU concern a lag time of 6 h; similar results were obtained for a lag time of 24 h. Figure 5 shows the cytotoxic effects of the triple association CDDP, 5-FU and FA on cell line CAL 27. For each experiment (Figure 5a and 5b) the dose response curves reflect a progressive increase in cytotoxicity when the FA concentration changed from 0 to 10-6 M. Figure 6 shows the iso-effect cuves at IC50. For a given IC50, use of FA 10-6 M, compared to conditions without FA, allowed reduction of the 5-FU concentration of from 42% (CDDP concentration-
Discussion
Most experimental results concerning use of 5-FU/FA associations have been obtained with colorectal carcinoma cell lines (Park et al., 1988) , leukaemic cells (Kane et al., 1987; Bertrand & Jolivet, 1989; Keyomarsi & Moran 1986 , and nasopharyngeal epidermoid cells (Kane et al., 1987) . This in vitro study confirms and strengthens the findings of these earlier reports by demonstrating that 5-FU activity on human head and neck squamous cell carcinoma cell lines can be potentiated by both CDDP and FA. Careful attention was paid to use of clinically relevant drug concentrations. 5-FU exposure at a dose of 10-100 ng ml-' for 5 days compares well with the concentrations reported in patients treated by continuous, 5-day infusions (Fraile et al., 1980) . Total concentration x time exposure (AUC) of CDDP ranged from 2 to 10 jg hr ml-'; pharmacokinetic studies for patients treated by 2 h infusions indicate AUC values between 1.75 and 8.33-gig hr ml' (Reece et al., 1989) . Repeated oral administration of leucovorin during 5 days leads to plasma concen- X2= 6.00 (2df), P < 0.05. trations of around 3 gLM ; in the present study, cells were exposed for 3-5 days to FA concentrations of 10-to 10-M. Keeping in mind the differences between in vitro and in vivo situations, our experimental conditions (drug concentrations and the durations of cell exposure) appear pharmacologically achievable, and permit more satisfactory extrapolation of the present findings to the actual clinical situations.
The experiments were performed in a non-folate depleted medium. Theoretically, use of a folate-depleted medium would have allowed more precise evaluation of the specific role of FA on the activity of 5-FU. However, as stressed by others (Park et al., 1988) , such tests could have resulted in overestimation of the effects of FA in comparison to physiological situations in which patients are not folate-deficient. On the other hand, the FA preparation contains an equimolar ratio of the natural (-1) and unnatural (-d) (Machover et al., 1986) . This raises the possibility that the -d FA might interfere with the isomer's enhancement of 5-FU cytotoxicity. This eventuality was not tested in the present study, because earlier reports (Bertrand & Jolivet, 1989) IC5o (no FA) **Values calculated using the regression lines on Figure 1 . treatment of advanced head and neck cancers (Kish et al., 1982; Amrein & Weitzman, 1985; Thyss et al., 1986) . However, up until now, there has been a lack of experimental investigations on the sequence-dependence of CDDP and 5-FU in this association. The present data suggest that CDDP administration before 5-FU potentiates the activity of the antimetabolite; simultaneous exposure to the two drugs results in simple additivity of their effects whereas the sequence 5-FU followed by CDDP gives lesser effects than could be expected. Considering that CDDP may promote increased intracellular retention of reduced folates (Scanlon et al., 1986) , pre-exposure to CDDP leading to increased 5-FU activity appears pharmacologically coherent (Houghton et al., 1982) . These findings confirm the report by Scanlon et al., 1986 ) concerning human ovarian carcinoma line A 2780 in culture; for these authors, CDDP followed by 5-FU was more cytotoxic than the opposite sequence or either drug used alone. However, these observations are in apparent contradiction with the recent work by Pratesi et al. (1988) , who analysed the sequence-dependence of the antitumour effect of a 5-FU-CDDP combination on chemically-induced colon tumours in a murine model. For these authors, 5-FU followed 24 h later by CDDP was the most active sequence. The relevance of their experimental model can be questioned, though, because of 5-FU alone had only marginal activity compared to CDDP, which was more effective.
Consistent clinical data having demonstrated 5-FU potentiation by CDDP (Kish et al., 1982; Amrein & Weitzman, 1985; Thyss et al., 1986; Scanlon et al., 1986) and FA (Machover et al., 1986; Rustum, 1989; O'Connell, 1989; Arbuck, 1989; Houghton et al., 1982) , it was tempting to test a combination of all three drugs. Not surprisingly, limited noncontrolled trials of this drug combination have appeared recently (Hart et al., 1989; Allegra et al., 1989; Fernandes et al., 1989; . To date, little attention has' been paid to the sequencing of the three drugs, a fundamental parameter influencing the effectiveness of this multiagent association. Our experimental data obtained with cell cultures of head and neck squamous cell carcinoma may shed some light on this important question. For a constant final cytotoxicity, administration of CDDP followed 6 h later by 5-FU plus FA (10-6 M) permitted reduction of the 5-FU dose between 24.2% and 42% or reduction of the CDDP dose between 13.8% and 72.7%. FA thus offers a means of significantly reducing exposure to potentially toxic drugs such as 5-FU and CDDP without loss of efficacy. Although definite benefits in terms of an improved therapeutic index remain to be proven clinically, these observations, obtained with clinically achievable drug concentrations, may allow the design of more rational therapeutic trials combining CDDP, 5-FU, and FA.
